Net income and diluted earnings per share for the 2008 full year were $4.41 billion and $3.27, respectively, compared with $4.61 billion and $3.38, respectively, for the 2007 full year.
The company recorded worldwide net revenues of $5.3 billion for the 2008 fourth quarter, a decrease of 7%, compared to $5.7 billion reported for the corresponding period of 2007.
Net income and diluted earnings per share for the 2008 fourth quarter were $960.4 million and $0.71, respectively, compared with $1.01 billion and $0.75, respectively, for the 2007 fourth quarter.
Bernard Poussot, chairman, president and CEO of Wyeth, said: “Wyeth met its expectations in 2008 despite external pressures. Our performance was led by strong, consistent contributions from our core product franchises – Enbrel, Prevnar and Nutritionals, revenue from new products, and ongoing cost containment efforts. Our diversified revenue base helped lessen the impact of the global economic downturn and the at-risk launch of generic versions of Protonix.”